Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

被引：0
|
作者：
Jun Guo
Jie Jin
Mototsugu Oya
Hirotsugu Uemura
Shunji Takahashi
Katsunori Tatsugami
Sun Young Rha
Jae-Lyun Lee
Jinsoo Chung
Ho Yeong Lim
Hsi Chin Wu
Yen Hwa Chang
Arun Azad
Ian D. Davis
Marlene J. Carrasco-Alfonso
Bhupinder Nanua
Jackie Han
Qasim Ahmad
Robert Motzer
机构：
[1] Peking University Cancer Hospital and Institute,Department Urology and Melanoma
[2] Peking University First Hospital,Department of Urology
[3] Keio University School of Medicine,Department of Urology
[4] Kindai University Faculty of Medicine,Department of Urology
[5] Cancer Institute Hospital,Department of Medical Oncology
[6] Japanese Foundation for Cancer Research,Department of Urology, Graduate School of Medical Sciences
[7] Kyushu University,Department of Oncology and Internal Medicine, Asan Medical Center
[8] Yonsei Cancer Center,Department of Urology
[9] Yonsei University College of Medicine,Division of Hematology
[10] University of Ulsan College of Medicine,Oncology
[11] Center for Prostate Cancer,Department of Urology
[12] National Cancer Center,Division of Urology, Department of Surgery
[13] Samsung Medical Center,Department of Medicine
[14] Sungkyunkwan University,Department of Medicine
[15] China Medical University Hospital,undefined
[16] Taipei Veterans General Hospital,undefined
[17] Monash University,undefined
[18] Monash University,undefined
[19] Eastern Health Clinical School,undefined
[20] Novartis Pharmaceuticals Corporation,undefined
[21] Novartis Pharmaceuticals Corporation,undefined
[22] Genitourinary Oncology Service,undefined
[23] Memorial Sloan-Kettering Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
Renal cell carcinoma; Pazopanib; Sunitinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
    Haanen, J. B. A. G.
    Larkin, J.
    Choueiri, T. K.
    Albiges, L.
    Rini, B. I.
    Atkins, M. B.
    Schmidinger, M.
    Penkov, K.
    Michelon, E.
    Wang, J.
    Mariani, M.
    di Pietro, A.
    Motzer, R. J.
    ESMO OPEN, 2023, 8 (03)
  • [42] Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial
    Sternberg, Cora N.
    Calabro, Fabio
    Bracarda, Sergio
    Carteni, Giacomo
    Lo Re, Giovanni
    Ruggeri, Enzo M.
    Basso, Umberto
    Gasparini, Giampietro
    Ciuffreda, Libero
    Ferrari, Vittorio
    Bonetti, Andrea
    Fea, Elena
    Gasparro, Donatello
    Tassinari, Davide
    Labianca, Roberto
    Masini, Cristina
    Fly, Kolette
    Zhang, Ke
    Hariharan, Subramanian
    Capaccetti, Barbara
    Porta, Camillo
    ONCOLOGY, 2015, 88 (05) : 273 - 280
  • [43] Comparison of the Efficacy and Safety of Nivolumab Plus Cabozantinib versus Sunitinib in the Treatment of Elderly Patients with Advanced Clear Cell Renal Cell Carcinoma
    Liu, Yanjie
    Meng, Ying
    Li, Mengmeng
    Dong, Yanjiao
    ARCHIVOS ESPANOLES DE UROLOGIA, 2024, 77 (05): : 584 - 590
  • [44] Sorafenib dose escalation in treatment-naive patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study
    Gore, Martin E.
    Jones, Robert J.
    Ravaud, Alain
    Kuczyk, Markus
    Demkow, Tomasz
    Bearz, Alessandra
    Shapiro, Joann
    Strauss, Uwe Phillip
    Porta, Camillo
    BJU INTERNATIONAL, 2017, 119 (06) : 846 - 853
  • [45] Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective
    Capri, Stefano
    Porta, Camillo
    Delea, Thomas E.
    CLINICAL THERAPEUTICS, 2017, 39 (03) : 567 - +
  • [46] Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1
    Tsukamoto, Taiji
    Shinohara, Nobuo
    Tsuchiya, Norihiko
    Hamamoto, Yasuo
    Maruoka, Masayuki
    Fujimoto, Hiroyuki
    Niwakawa, Masashi
    Uemura, Hirotsugu
    Usami, Michiyuki
    Terai, Akito
    Kanayama, Hiro-omi
    Sumiyoshi, Yoshiteru
    Eto, Masatoshi
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (01) : 17 - 24
  • [47] A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
    Lara Jr, Primo N.
    Villanueva, Luis
    Ibanez, Carolina
    Erman, Mustafa
    Lee, Jae Lyun
    Heinrich, Daniel
    Lipatov, Oleg Nikolaevich
    Gedye, Craig
    Gokmen, Erhan
    Acevedo, Alejandro
    Semenov, Andrey
    Park, Se Hoon
    Gafanov, Rustem Airatovich
    Kose, Fatih
    Jones, Mark
    Du, Xiaoqi
    Munteanu, Mihaela
    Perini, Rodolfo
    Choueiri, Toni K.
    Motzer, Robert J.
    BMC CANCER, 2024, 23 (SUPPL 1)
  • [48] Avelumab D axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
    Choueiri, T. K.
    Penkov, K.
    Uemura, H.
    Campbell, M. T.
    Pal, S.
    Kollmannsberger, C.
    Lee, J. L.
    Venugopal, B.
    Eertwegh, A. J. M. van den
    Negrier, S.
    Gurney, H.
    Albiges, L.
    Berger, R.
    Haanen, J. B. A. G.
    Juarez, V. Oyervides
    Rini, B. I.
    Larkin, J.
    Nole, F.
    Schmidinger, M.
    Atkins, M. B.
    Tomita, Y.
    Ellers-Lenz, B.
    Hoffman, J.
    Sandner, R.
    Wang, J.
    di Pietro, A.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2025, 36 (04) : 387 - 392
  • [49] Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
    Zhang, Hai-Liang
    Sheng, Xi-Nan
    Li, Xue-Song
    Wang, Hong-Kai
    Chi, Zhi-Hong
    He, Zhi-Song
    Ye, Ding-Wei
    Guo, Jun
    BMC CANCER, 2017, 17
  • [50] Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
    Hai-Liang Zhang
    Xi-Nan Sheng
    Xue-Song Li
    Hong-Kai Wang
    Zhi-Hong Chi
    Zhi-Song He
    Ding-Wei Ye
    Jun Guo
    BMC Cancer, 17
12345